Gilead Named One of America’s Most JUST Companies by JUST Capital and CNBC

Rhea-AI Summary

Gilead Sciences, Inc. has been named one of America's Most JUST Companies, ranking fifth in the Pharmaceuticals and Biotech industry. The company's commitment to stakeholder engagement, sustainability, and creating a healthier world has been recognized. Gilead's ESG strategy focuses on health equity, access to medicines, inclusive workplace, and environmental sustainability.

Company Also Ranked in Top 5 of Pharmaceuticals and Biotech Industry

FOSTER CITY, CA / ACCESSWIRE / February 20, 2024 / Gilead Sciences, Inc. (Nasdaq:GILD) announced the company has been named one of America's Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead's longstanding commitment to operate responsibly by prioritizing stakeholder engagement - including with the patients and communities the company serves, employees and shareholders - while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.

"We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations," said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. "We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve."

Gilead's Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead's commitment to ESG include:

• Expanding health equity around the world through programs that promote health system sustainability, strengthen infrastructure and provide education and financial support
• Increasing access to medicines in low- and lower-middle income countries, including voluntary licensing for Gilead's HIV, hepatitis C and COVID-19 treatments
• Creating an inclusive workplace that is representative of the diverse communities the company serves
• Continuing to evolve the company's environmental sustainability program while progressing against ambitious goals focused on carbon, water, waste and packaging

Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans' attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/

This recognition follows Gilead's recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.

Details on Gilead's ESG commitments, goals and progress can be found in the company's Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead's commitment to ESG at https://www.gilead.com/purpose/esg.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

Jacquie Ross, Investors
investor_relations@gilead.com

Meaghan Smith, Media
public_affairs@gilead.com

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:

Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

FAQ

What ranking did Gilead Sciences, Inc. achieve in the Pharmaceuticals and Biotech industry?

Gilead Sciences, Inc. ranked fifth in the Pharmaceuticals and Biotech industry.

What is Gilead Sciences, Inc.'s focus in its ESG strategy?

Gilead Sciences, Inc.'s ESG strategy focuses on health equity, access to medicines, inclusive workplace, and environmental sustainability.

How does Gilead Sciences, Inc. contribute to expanding health equity globally?

Gilead Sciences, Inc. contributes to expanding health equity globally through programs that promote health system sustainability, strengthen infrastructure, and provide education and financial support.

What does Gilead Sciences, Inc. aim to achieve through its ESG strategy?

Gilead Sciences, Inc. aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner.

Who mentioned Gilead Sciences, Inc. as one of America's Most JUST Companies?

Gilead Sciences, Inc. was mentioned by JUST Capital and CNBC as one of America's Most JUST Companies.